NA Psychedelic Drugs Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.3 OVERVIEW OF NORTH AMERICA PSYCHEDELIC DRUGS MARKET 26
1.4 LIMITATIONS 28
1.5 MARKETS COVERED 29
2 MARKET SEGMENTATION 31
2.1 MARKETS COVERED 31
2.2 GEOGRAPHICAL SCOPE 32
2.3 YEARS CONSIDERED FOR THE STUDY 33
2.4 CURRENCY AND PRICING 33
2.5 DBMR TRIPOD DATA VALIDATION MODEL 34
2.6 MULTIVARIATE MODELLING 37
2.7 SOURCE LIFELINE CURVE 37
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 38
2.9 DBMR MARKET POSITION GRID 39
2.10 MARKET APPLICATION COVERAGE GRID 40
2.11 VENDOR SHARE ANALYSIS 41
2.12 SECONDARY SOURCES 42
2.13 ASSUMPTIONS 42
3 EXECUTIVE SUMMARY 43
4 PREMIUM INSIGHTS 47
4.1 EPIDEMIOLOGY 48
4.2 PIPELINE ANALYSIS 50
5 REGULATORY FRAMEWORK: NORTH AMERICA PSYCHEDELIC DRUGS MARKET 52
5.1 REGULATORY SCENARIO IN THE U.S. 52
5.2 REGULATORY SCENARIO IN THE U.K. 53
5.3 REGULATORY SCENARIO IN INDIA 54
5.4 REGULATORY SCENARIO IN UAE 54
5.5 REGULATORY SCENARIO IN AFRICA 55
5.6 REGULATORY SCENARIO IN BRAZIL 55

6 MARKET OVERVIEW 57
6.1 DRIVERS 59
6.1.1 GROWING ACCEPTANCE OF PSYCHEDELIC DRUGS FOR TREATING DEPRESSION 59
6.1.2 INCREASING PREVALENCE OF DEPRESSION AND MENTAL DISORDERS 61
6.1.3 RISING AWARENESS TOWARDS MENTAL HEALTH 66
6.1.4 ONGOING CLINICAL TRIALS 67
6.1.5 RISE IN PRODUCT APPROVALS 68
6.2 RESTRAINTS 68
6.2.1 STRINGENT REGULATIONS FOR PSYCHEDELIC DRUGS 68
6.2.2 HIGH COST OF PSYCHEDELIC DRUGS 71
6.2.3 PATENT EXPIRY OF PSYCHEDELIC DRUGS 74
6.3 OPPORTUNITIES 74
6.3.1 INCREASING R&D ACTIVITIES IN PSYCHEDELIC DRUGS 74
6.3.2 BREAKTHROUGH THERAPY DESIGNATION BY REGULATORY AUTHORITY 76
6.3.3 UPCOMING REHABILITATION CENTERS 78
6.3.4 AVAILABILITY OF CERTIFIED HEALTHCARE PROFESSIONALS 78
6.4 CHALLENGES 78
6.4.1 SIDE EFFECTS ASSOCIATED WITH PSYCHEDELIC DRUGS 78
6.4.2 RISE IN ILLEGAL ALTERNATIVES 79
6.4.3 AVAILABILITY OF OTHER TREATMENT OPTIONS 80
7 COVID-19 IMPACT ON NORTH AMERICA PSYCHEDELIC DRUGS MARKET 81
7.1 IMPACT ON PRICE 81
7.2 IMPACT ON DEMAND 81
7.3 IMPACT ON SUPPLY CHAIN 82
7.4 STRATEGIC DECISIONS FOR MANUFACTURERS 82
7.5 CONCLUSION 83
8 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY TYPE 84
8.1 OVERVIEW 85
8.2 EMPATHOGENS 88
8.3 DISSOCIATIVES 88
8.4 OTHERS 89
9 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY SOURCE 91
9.1 OVERVIEW 92
9.2 SYNTHETIC 95
9.3 NATURAL 95

10 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY DRUGS 97
10.1 OVERVIEW 98
10.2 GAMMA-HYDROXYBUTYRIC ACID 101
10.3 KETAMINE 101
10.4 PSILOCYBIN 102
10.5 OTHERS 103
11 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY APPLICATION 105
11.1 OVERVIEW 106
11.2 NARCOLEPSY 109
11.3 TREATMENT RESISTANT DEPRESSION 109
11.4 MAJOR DEPRESSIVE DISORDER 110
11.5 OPIATE ADDICTION 111
11.6 POST-TRAUMATIC STRESS DISORDER 112
11.7 OTHERS 113
12 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION 114
12.1 OVERVIEW 115
12.2 ORAL 118
12.3 INHALATION 118
12.4 INJECTABLE 119
13 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY END USER 121
13.1 OVERVIEW 122
13.2 HOSPITALS 125
13.3 SPECIALTY CLINICS 125
13.4 HOMECARE 126
13.5 OTHERS 127
14 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL 128
14.1 OVERVIEW 129
14.2 HOSPITALS PHARMACY 132
14.3 RETAIL PHARMACY 132
14.4 ONLINE PHARMACY 133
15 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY REGION 135
15.1 NORTH AMERICA 136
15.1.1 U.S. 143
15.1.2 CANADA 145
15.1.3 MEXICO 147
16 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: COMPANY LANDSCAPE 149
16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 149
17 SWOT ANALYSIS 150
18 COMPANY PROFILE 151
18.1 JAZZ PHARMACEUTICALS, INC. 151
18.1.1 COMPANY SNAPSHOT 151
18.1.2 REVENUE ANALYSIS 151
18.1.3 COMPANY SHARE ANALYSI 152
18.1.4 PRODUCT PORTFOLIO 152
18.1.5 RECENT DEVELOPMENTS 153
18.2 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 154
18.2.1 COMPANY SNAPSHOT 154
18.2.2 REVENUE ANALYSIS 154
18.2.3 COMPANY SHARE ANALYSIS 155
18.2.4 PRODUCT PORTFOLIO 155
18.2.5 RECENT DEVELOPMENTS 155
18.3 PFIZER INC. 157
18.3.1 COMPANY SNAPSHOT 157
18.3.2 REVENUE ANALYSIS 157
18.3.3 COMPANY SHARE ANALYSIS 158
18.3.4 PRODUCT PORTFOLIO 158
18.3.5 RECENT DEVELOPMENTS 158
18.4 AVADEL 160
18.4.1 COMPANY SNAPSHOT 160
18.4.2 REVENUE ANALYSIS 160
18.4.3 PRODUCT PORTFOLIO 161
18.4.4 RECENT DEVELOPMENTS 161
18.5 CELON PHARMA S.A. 162
18.5.1 COMPANY SNAPSHOT 162
18.5.2 PIPELINE PRODUCT PORTFOLIO 162
18.5.3 RECENT DEVELOPMENTS 162
18.6 COMPASS 163
18.6.1 COMPANY SNAPSHOT 163
18.6.2 PIPELINE PRODUCT PORTFOLIO 163
18.6.3 RECENT DEVELOPMENTS 163

18.7 CYBIN CORP. 164
18.7.1 COMPANY SNAPSHOT 164
18.7.2 PIPELINE PRODUCT PORTFOLIO 164
18.7.3 RECENT DEVELOPMENT 164
18.8 DEMERX 165
18.8.1 COMPANY SNAPSHOT 165
18.8.2 PIPELINE PRODUCT PORTFOLIO 165
18.8.3 RECENT DEVELOPMENT 165
18.9 EMPATHBIO 166
18.9.1 COMPANY SNAPSHOT 166
18.9.2 PIPELINE PRODUCT PORTFOLIO 166
18.9.3 RECENT DEVELOPMENT 166
18.10 F. HOFFMANN-LA ROCHE LTD 167
18.10.1 COMPANY SNAPSHOT 167
18.10.2 REVENUE ANALYSIS 167
18.10.3 PRODUCT PORTFOLIO 168
18.10.4 RECENT DEVELOPMENT 168
18.11 GABA THERAPEUTICS, INC. 169
18.11.1 COMPANY SNAPSHOT 169
18.11.2 PIPELINE PRODUCT PORTFOLIO 169
18.11.3 RECENT DEVELOPMENT 169
18.12 HIKMA PHARMACEUTICALS PLC 170
18.12.1 COMPANY SNAPSHOT 170
18.12.2 REVENUE ANALYSIS 170
18.12.3 PRODUCT PORTFOLIO 171
18.12.4 RECENT DEVELOPMENTS 171
18.13 MIND MEDICINE INC. 172
18.13.1 COMPANY SNAPSHOT 172
18.13.2 PIPELINE PRODUCT PORTFOLIO 172
18.13.3 RECENT DEVELOPMENTS 172
18.14 NEURORX, INC. 173
18.14.1 COMPANY SNAPSHOT 173
18.14.2 PIPELINE PRODUCT PORTFOLIO 173
18.14.3 RECENT DEVELOPMENTS 174
18.15 PHARMATHER HOLDINGS LTD. 175
18.15.1 COMPANY SNAPSHOT 175
18.15.2 PIPELINE PRODUCT PORTFOLIO 175
18.15.3 RECENT DEVELOPMENTS 176

18.16 USONAINSTITUTE.ORG 177
18.16.1 INSTITUTE SNAPSHOT 177
18.16.2 PIPELINE PRODUCT PORTFOLIO 177
18.16.3 RECENT DEVELOPMENTS 177
18.17 VERRIAN 178
18.17.1 COMPANY SNAPSHOT 178
18.17.2 PRODUCT PORTFOLIO 178
18.17.3 RECENT DEVELOPMENT 178
19 QUESTIONNAIRE 179
20 RELATED REPORTS 183